X4 Pharmaceuticals (XFOR) Operating Expenses (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Operating Expenses for 10 consecutive years, with $23.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 15.42% year-over-year to $23.6 million; the trailing twelve-month figure through Jun 2026 stood at $100.8 million (down 24.25% YoY), and the FY2025 full-year result was $116.2 million, up 198.37% from the prior year.
• Operating Expenses improved to $23.6 million in Q2 2026 per XFOR's latest filing, from $22.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $37.3 million in Q1 2024 and bottomed at $20.2 million in Q3 2022.
• Historically, Operating Expenses has averaged $27.8 million across 5 years, with a median of $26.6 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses surged 46.22% in 2024, then tumbled 33.15% in 2026.
• Over 5 years, Operating Expenses stood at $25.6 million in 2022, then fell by 1.48% to $25.2 million in 2023, then jumped by 46.22% to $36.8 million in 2024, then retreated by 29.7% to $25.9 million in 2025, then slipped by 8.97% to $23.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $23.6 million, $22.4 million, and $25.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.